Glaukos (NYSE:GKOS) Announces Quarterly Earnings Results

Glaukos (NYSE:GKOS) issued its quarterly earnings data on Tuesday. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05), FiscalAI reports. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The firm had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million.

Glaukos Price Performance

Shares of GKOS stock traded down $2.39 on Tuesday, hitting $107.08. 1,252,075 shares of the company’s stock were exchanged, compared to its average volume of 833,944. The company has a 50 day moving average of $114.66 and a 200 day moving average of $98.20. The stock has a market cap of $6.15 billion, a P/E ratio of -69.53 and a beta of 0.70. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. Glaukos has a 12 month low of $73.16 and a 12 month high of $161.78.

Insider Transactions at Glaukos

In other Glaukos news, Director Marc Stapley sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total value of $1,915,650.00. Following the sale, the director owned 37,449 shares in the company, valued at $4,782,611.79. This trade represents a 28.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $107.27, for a total transaction of $536,350.00. Following the transaction, the director owned 34,905 shares of the company’s stock, valued at $3,744,259.35. This trade represents a 12.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 310,315 shares of company stock valued at $36,011,634. 5.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC raised its position in Glaukos by 2.6% in the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after purchasing an additional 198 shares during the last quarter. Jones Financial Companies Lllp increased its stake in shares of Glaukos by 1,405.9% in the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock valued at $252,000 after buying an additional 2,390 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Glaukos by 41.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after buying an additional 67,668 shares during the period. M&T Bank Corp bought a new position in Glaukos in the 2nd quarter valued at approximately $203,000. Finally, Gamco Investors INC. ET AL boosted its position in Glaukos by 10.7% during the 2nd quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock worth $826,000 after buying an additional 773 shares during the period. Institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group reissued a “buy” rating and issued a $138.00 target price on shares of Glaukos in a research report on Friday, January 9th. Stifel Nicolaus lifted their price objective on shares of Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Piper Sandler restated an “overweight” rating and set a $165.00 target price on shares of Glaukos in a research report on Wednesday, January 14th. JPMorgan Chase & Co. raised their target price on shares of Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Finally, UBS Group lifted their price target on shares of Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $132.54.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.